Email: Password:
| Forgot Password
Nav_logo

A free online accredited CPD program for healthcare professionals

Type 2 Diabetes: New Guidelines go Above and Beyond A1C Lowering

1.50 Canadian Council On Continuing Education In Pharmacy (CCCEP) CEU(s) / /

Program available online until: October 09, 2019



This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP)
for 1.50 CEU(s).

CCCEP File Number: 1066-2018-2546-I-P

New Guidelines for Cardiovascular Risk in Type 2 Diabetes

Content/Programs/CaseStudy/T2D_NewGuidelines_10299/assets/images/GettyImages-922526244.jpg

Cardiovascular disease is the leading cause of morbidity and mortality in people with type 2 diabetes (T2DM). Evidence from recent cardiovascular safety trials in T2DM is changing clinical and pharmacy practice in new ways that go beyond A1C lowering. This program will support pharmacists in understanding how the pharmaceutical approaches for these patients has changed in the April 2018 update to the Diabetes Canada guidelines, and the evolving role of pharmacists in vascular and renal protection.

Planning Committee

  • Sean Wharton, MD, PharmD.
  • Jessie Haggai, BSc Pharm, CDE.
  • Rob Roscoe, BSc Pharm, ACPR, CDE, CPT, CDE.

Learning Objectives

After completion of the program, the participant will be able to:

  • Describe how cardiovascular outcomes trials have informed changes to the Diabetes Canada treatment algorithm for type 2 diabetes mellitus (T2DM).
  • Analyze the benefits and risks of antihyperglycemic treatments that have demonstrated cardiovascular benefit in second-line treatment of T2DM.
  • Counsel patients with T2DM to support vascular protection in the pharmacy.

Ask the Expert Sean Wharton, MD, PharmD

  1. How has the approach to choosing the first add-on after metformin changed with the new guidelines?
  2. Are patients who have T2DM without prior CVD also at increased cardiovascular risk?
  3. When should patients be identified as being at risk of volume depletion?
  4. What are the risks and benefits of canagliflozin therapy for patients with T2DM?
  5. If empagliflozin and canagliflozin may delay progression of nephropathy, why are they contraindicated at certain levels of renal impairment?
  6. What is the risk of hypoglycemia when liraglutide, empagliflozin, or canagliflozin are used as add-on treatments in T2DM?
Content/Programs/CaseStudy/T2D_NewGuidelines_10299/assets/thumbnails/DrWharton_LP.jpg

mdBriefCase is the practical choice to earn your CPD Credits

Icon of multiple pages

20+ therapeutic areas

100+ programs each year.

Icon of multiple pages

Quality, accredited content

Developed by leading specialists and peer-reviewed by experts at respected institutions.

Icon of multiple pages

Online convenience

Save time and money.

Join 45,000+ of your colleagues

Create your free account today